#ESCCongress2023. Semaglutide Improves Symptoms in Obese Patients with Preserved Ejection Fraction Heart Failure

According to a study presented at the ESC 2023 Congress, semaglutide improves symptoms of heart failure, increases exercise tolerance, and causes significant weight loss in heart failure patients with preserved ejection fraction and obesity. These results represent the largest benefit associated with a therapeutic agent for obese patients. in heart failure with preserved ejection fraction.

Main findings after 52 weeks of therapy:

  • The KCCQ-CSS symptom score changed by almost 17 points in people treated with semaglutide. and almost 9 points in the control group
  • Therapy with semaglutide was associated with a mean change in body weight of more than 13%, while in people who received placebo, this percentage was almost 3%.
  • A 6-minute walk showed a mean change of more than 21 meters in people taking semaglutide therapy.compared to more than 1 meter in the control group
  • Semaglutide administration was associated with a reduction in inflammation, lowering C-reactive protein values ​​by an average of almost 45%.compared to more than 7% in the control group
  • NT-proBNP levels decreased by almost 21% in people treated with semaglutide. and more than 5% in those who received placebo
Photo Source: Unsplash

Among people with heart failure, about half have a preserved ejection fraction. Most of these patients are overweight or obese, and excess adipose tissue may play a role in the development and progression of heart failure with preserved ejection fraction.

The presence of obesity is accompanied by more pronounced symptoms of heart failure, such as shortness of breath, exercise intolerance, edema, which reduces the quality of life of these patients. Therapeutic options are limited, and there are no approved drugs specifically targeting the obesity-associated HF phenotype.

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that causes significant weight loss in overweight or obese people. The STEP-HFpEF study, which evaluates the effects of semaglutide in people with obesity and heart failure with preserved ejection fraction, is a randomized clinical trial conducted at 96 centers in 13 countries in Asia, Europe, North and South America.

They included almost 530 patients with heart failure with preserved ejection fraction (more than 45%), with a BMI (body mass index) of at least 30, symptoms of heart failure, functional limitations and decreased exercise tolerance.. Half of the patients received weekly semaglutide therapy for 52 weeks, while the other half received placebo. Severe side effects were reported in more than 13% of people taking semaglutide and nearly 30% of people taking placebo.

Read also:

Source link

Leave a Comment